Johnson & Johnson reports Phase 1 data for dual‑antigen bispecific therapy in advanced prostate cancer
Johnson & Johnson presented first‑in‑human Phase 1 results for the combination of pasritamig and JNJ‑9401 in patients with metastatic castration‑resistant prostate cancer. At the identified Phase 2 dose of 300 mg pasritamig given intravenously every six weeks together with 200 mg JNJ‑9401 subcutaneously every six weeks, 73 % of 15 patients achieved a PSA decline of at least 50 % and 47 % achieved a decline of at least 90 %. The safety profile was favorable, with no grade 3 or higher treatment‑related adverse events and only mild cytokine release syndrome in 20 % of patients. The company plans to advance the regimen into a Phase 3 trial.
Why it matters
The company states that the encouraging efficacy and safety data justify moving the regimen into Phase 3, potentially adding a new immunotherapy option for heavily pre‑treated prostate cancer patients.
Key facts
- 1The Phase 2 dose identified is 300 mg pasritamig administered intravenously every six weeks combined with 200 mg JNJ‑9401 subcutaneously every six weeks. urotoday.com
- 2At a data cutoff of June 15 2026, 144 patients had been enrolled in the study. prnewswire.com
- 3Among the 15 patients treated at the recommended regimen, 11 (73 %) achieved a PSA reduction of at least 50 %. prnewswire.com
- 4Seven of those 15 patients (47 %) achieved a PSA reduction of at least 90 %. prnewswire.com
- 5No grade 3 or higher treatment‑related adverse events were reported in the early analysis. prnewswire.com
- 6Cytokine release syndrome occurred in three patients (20 %) and was limited to grade 1 fever without need for tocilizumab. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.